HOME / SCIENCE / Strategy

Strategy

Strategy

Since 2016, cancer is the second most common cause of death, accounting for just over a quarter of all deaths worldwide. Despite of tremendous amount of effort to understand cancer and to fight against it, cancer is remaining as a formidable and devastating disease of our time. In order to give hope to cancer patients and their families, we are committed to develop innovative small molecule anti-cancer medicine.

Txinno Bioscience is developing anti-cancer treatments focused on two intertwined aspects of physiology of tumor tissue.

The first one is defined as tumor-extrinsic factors which are various signaling pathways operating in stromal cells other than tumor cells and promoting cancer cells to survive. Corresponding assets are ENPP1 inhibitor, “Target L” inhibitor and ”Target Z” inhibitor controlling Tumor microenvironment

The other one is defined as tumor-intrinsic factors which are either genes or signaling pathways of tumor cells to directly control tumor cell proliferation or survival. Corresponding assets are ULK1 inhibitor, ULK1 TPD , and ”Target W” TPD related to cancer vulnerability.

Global Pharmaceutical Demand and Tumor Heterogeneity Immune Oncology / targeted therapies

  • Reflecting Global Pharmaceutical Demand: Focus on the development of immune microenvironment-modulating therapies and targeted therapy of cancer vulnerability.

  • Reflecting Tumor Heterogeneity: Tumors are not merely simple masses of malignant cells but complex cell tissues formed by the transformation of various types of cells.

Modulation of tumor microenvironment (TME)

Delivery Strategies and Engineering Technologies in Cancer Immunotherapy 2022, P19-61


Front. Gastroenterol., 20 September 2022

Cancer immunotherapy is a strategy that activates the patient’s immune system to recognize and eliminate cancer cells, strengthening the body’s own defense mechanisms rather than directly attacking the tumor. NK cells, dendritic cells (DCs), macrophages, and cytotoxic T cells work together to remove tumors, and this process is heavily influenced by the tumor microenvironment (TME).

TME-modulating immunotherapies maximize immune activation by enhancing T-cell and NK-cell activity, inducing macrophage repolarization, improving antigen presentation, and suppressing immunosuppressive cells—thereby converting an immunosuppressive TME into an inflammatory one.

TXN10128 from Txinno BioScience is an innate-immunity-based anticancer therapy targeting ENPP1. By activating the cGAS–STING pathway, it converts “immune-excluded (cold)” tumors into “immune-inflamed (hot)” tumors, thereby strengthening immune responses. When combined with chemotherapy or ADCs, it enhances tumor-infiltrating T-cell responses and improves clinical efficacy.